Using highly expressed circular RNAs to substantially enhance protein expression yields in mammalian cells
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CHIMERNA THERAPEUTICS, INC.
- Proposal award date
- 2020-08-01
- Contract end date
- 2021-01-31
- UEI
- JMH6UEKMAE65
- Solicitation number
- PA19-272
- Topic code
- 400
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Synthetic biology approaches for bio-orthogonal labeling of circular RNAs
- Development of circRNA manufacturing platform in yeast
- A Novel TDP-43-Targeting Circular RNA to Treat Amyotrophic Lateral Sclerosis (ALS)
- Next-generation RNA synthesis and labeling kits
- Circular RNA aptamers to regulate iron homeostasis in iron overload disorders
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Platform for Optimizing Yield and Quality of Therapeutic AAV Vector Manufacturing via Synthetic Helper Genes
- Ultra-low-temperature (6 K) static NMR-DNP for metalloproteins, proteins in cells, and materials
- Dynamical Diffraction Analysis for 3D Electron Crystallography
- Break Wave lithotripsy to fragment large kidney stones
Research funding history
8 SBIR/STTR records share this UEI (2020–2025). Reported award amounts total $3,493,039. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services